EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)

Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The SPRING study

L Puig iD, E Daudén iD, M Cuervas-Mons iD, C Novella, C Guisado

Journal of the European Academy of Dermatology and Venereology · 2025-03 · 39 (S1) · 27-37

DOI: 10.1111/jdv.19403 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 24.08.2023. Verfasst von L Puig und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Janssen Cilag S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Guselkumab is a monoclonal antibody that blocks the IL‐23 pathway with proven efficacy and tolerability in the treatment of moderate‐to‐severe plaque psoriasis.

Objectives

To assess the persistence, effectiveness and safety of guselkumab in patients with moderate‐to‐severe psoriasis in real clinical practice in Spain.

Methods

SPRING was a Phase IV, retrospective and non‐interventional study analysing patients with moderate‐to‐severe plaque psoriasis who had initiated guselkumab under clinical practice conditions at least 12 months before inclusion in the study. The primary endpoint was persistence (non‐persistence: discontinuation or interruption ≥90 days). Effectiveness was assessed using the Psoriasis Area Severity Index (PASI) and Investigator Global Assessment (IGA). Dermatology Life Quality Index (DLQI) and safety were also evaluated.

Results

A total of 284 patients were included between September 2020 and June 2021. The 1‐year probability of persistence was 89.6% (86.1%–93.3%). The 1‐year probability of persistence was also calculated according to prior biologic treatment, being 90.3% for biologic‐naïve patients and 89.5% for patients who received one or more biologic therapies before guselkumab. Additionally, patients were also classified based on the frequency of the administration of guselkumab treatment; the 1‐year probability of persistence was 91.9% in patients receiving guselkumab according to the Summary of Product Characteristics and 89.3% in patients with lengthened intervals of administration. After 1 year, PASI 90 was achieved by 56.4% of patients, IGA 0/1 response and BSA 4‐point reduction) in the DLQI score at 1 year. Twenty‐six adverse reactions (4 of them serious) were reported in 16 patients.

Conclusions

This study suggests that guselkumab has high persistence in real clinical practice in Spain, independently of the previous biologic treatments and changes in the frequency of treatment. Effectiveness and safety are consistent with previously published data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleFemaleRetrospective StudiesMiddle AgedSeverity of Illness IndexAdultTreatment OutcomeQuality of LifeSpainAged

Substanzen

guselkumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Department of Dermatology, Instituto de Investigación Sanitaria (IIS-HP) Hospital Universitario de La Princesa, Madrid, Spain.
  • Medical Department, Janssen Cilag, S.A., Madrid, Spain.

ORCID-Profile: L Puig, E Daudén, M Cuervas-Mons

Förderung

  • Janssen Cilag S.A.

Zitieren

APA

Puig, L., Daudén, E., Cuervas-Mons, M., Novella, C., & Guisado, C. (2025). Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The SPRING study. Journal of the European Academy of Dermatology and Venereology, 39(S1), 27-37. https://doi.org/10.1111/jdv.19403

Vancouver

Puig L, Daudén E, Cuervas-Mons M, Novella C, Guisado C. Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The SPRING study. Journal of the European Academy of Dermatology and Venereology. 2025;39(S1):27-37. doi:10.1111/jdv.19403

BibTeX
@article{Puig2025,
  author = {Puig, L and Daudén, E and Cuervas-Mons, M and Novella, C and Guisado, C},
  title = {Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The SPRING study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {S1},
  pages = {27--37},
  doi = {10.1111/jdv.19403}
}
Kostenlos starten →